Table 2.
Cox regression analysis for time to HBV reactivation (analysis population, n = 326)
| Effect/covariate* | Time to HBV reactivation (univariate)† | Time to HBV reactivation (multivariate) | ||||
|---|---|---|---|---|---|---|
| Crude HR | 95% CI | P | Adjusted HR | 95% CI | P | |
| Age at baseline (continuous, by 10 y) | 1.24 | 0.90-1.79 | .2260 | 1.63 | 1.00-2.37 | .0351 |
| Sex (male vs female) | 1.51 | 0.68-3.37 | .3110 | 1.19 | 0.50-2.86 | .6923 |
| ECOG performance status at baseline (2 vs 0 or 1) | 1.04 | 0.25-4.42 | .9531 | NA | NA | NA |
| Lymphoma type‡ (DLBCL [GOYA] vs non-DLBCL [GALLIUM]) | 3.06 | 1.04-9.04 | .0430 | 3.76 | 1.09-12.96 | .0356 |
| IPI, FLIPI score (high-intermediate/high vs low/intermediate/low-intermediate) | 1.51 | 0.71-3.21 | .2877 | NA | NA | NA |
| Anti-HBs at baseline (negative vs positive) | 4.35 | 1.93-9.78 | .0004 | 4.00 | 1.71-9.37 | .0014 |
| HBV DNA level at baseline, IU/mL (detectable vs not detectable) | 12.42 | 4.96-31.07 | <.0001 | 18.22 | 6.04-54.93 | <.0001 |
| Prophylactic NAT (yes vs no) | 0.19 | 0.04-0.79 | .0226 | 0.09 | 0.02-0.41 | .0018 |
| Antibody treatment group (G-Chemo vs R-Chemo) | 1.94 | 0.89-4.24 | .0963 | 1.79 | 0.78-4.16 | .1748 |
| Chemotherapy group§ (CHOP vs non-CHOP) | 1.86 | 0.44-7.94 | .3990 | NA | NA | NA |
NA, not applicable.
*
Reference groups for each factor are shown in bold. Race/ethnicity was not included in the model.
†
Factors with P < .2 by univariate analysis, baseline age, and sex were included in the multivariate analysis; 95% Wald confidence interval and P value for Wald test.
‡
Includes DLBCL patients from GOYA and non-DLBCL patients from GALLIUM.
§
Includes patients from both GOYA and GALLIUM.